Skip to Main Content
Try STAT+ TODAY
Trending:
Biotech
Health
First Opinion
STAT+
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Politics
STAT+

Here’s where Democrats’ resurrected drug pricing talks are headed

  • Nicholas Florko
  • Rachel Cohrs

By Nicholas Florko and Rachel Cohrs Nov. 2, 2021

Reprints
D.C. Insight IMAGE
Alex Hogan/STAT

You’re reading the web edition of D.C. Diagnosis, STAT’s weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox.

Where Democrats’ resurrected drug pricing talks are headed

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Authors Reprints

Nicholas Florko

Nicholas Florko

Reporter, Commercial Determinants of Health

Nicholas Florko reports on the commercial determinants of health.

Rachel Cohrs

Rachel Cohrs

Washington Correspondent

Rachel reports on the intersection of politics and health policy.

Tags

Create a display name to comment

This name will appear with your comment

Deferral of primary care signals a troubled future for…
Deferral of primary care signals a troubled future for Americans’ health
Limits of ‘Fauci effect’: infectious disease applicants plummet, and…
Limits of ‘Fauci effect’: infectious disease applicants plummet, and hospitals are scrambling
Eli Lilly tightens access to diabetes drug, frustrating some…
Eli Lilly tightens access to diabetes drug, frustrating some people with obesity
ARPA-H’s new director wants to go on a hiring…
ARPA-H’s new director wants to go on a hiring spree
FDA chief calls agency’s food program ‘under-supported, under-resourced’
FDA chief calls agency’s food program ‘under-supported, under-resourced’
The prices of 7 drugs were hiked without proof…
The prices of 7 drugs were hiked without proof of new benefits, costing the U.S. $805…

Recommended Stories